Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 12, Issue 537, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aay9924
Keywords
-
Categories
Funding
- Alberta Innovates-Health Solutions (AIHS)
- Alberta Cancer Foundation
- Ronald and Irene Ward Foundation
- Canadian Institutes of Health Research
- Brain Canada platform grant
- Vanier Canada Graduate Scholarship
- University of Calgary Eyes High postdoctoral scholarship
- AIHS
- Branch Out Neurological Foundation
- CIHR
- ACHRI
Ask authors/readers for more resources
Glioblastomas are generally incurable partly because monocytes, macrophages, and microglia in afflicted patients do not function in an antitumor capacity. Medications that reactivate these macrophages/microglia, as well as circulating monocytes that become macrophages, could thus be useful to treat glioblastoma. We have discovered that niacin (vitamin B3) is a potential stimulator of these inefficient myeloid cells. Niacin-exposed monocytes attenuated the growth of brain tumor-initiating cells (BTICs) derived from glioblastoma patients by producing anti-proliferative interferon-alpha 14. Niacin treatment of mice bearing intracranial BTICs increased macrophage/microglia representation within the tumor, reduced tumor size, and prolonged survival. These therapeutic outcomes were negated in mice depleted of circulating monocytes or harboring interferon-alpha receptor-deleted BTICs. Combination treatment with temozolomide enhanced niacin-promoted survival. Monocytes from glioblastoma patients had increased interferon-alpha 14 upon niacin exposure and were reactivated to reduce BTIC growth in culture. We highlight niacin, a common vitamin that can be quickly translated into clinical application, as an immune stimulator against glioblastomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available